PAVM

PAVmed Inc.

5.20 USD

Last updated Sep 4, 20:54 UTC

Yesterday HIGH

$5.36

Yesterday LOW

$5.05

52w HIGH

$28.44

52w LOW

$3.88

EPS

-0.27

PE

-19.26

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

PAVmed Inc. stock is up 3.17% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Thu Aug 27, 2026

Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.
Benzinga Insights

Fri Aug 14, 2026

PAVmed Q2 2026 Earnings Call: Complete Transcript

On Friday, PAVmed (NASDAQ:PAVM) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Benzinga Newsdesk

Fri Aug 14, 2026

PAVmed Q2 Adj. EPS $(0.27) Beats $(0.58) Estimate, Sales $33.000K Miss $72.000K Estimate

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.58) by 53.45 percent. This is a 82 percent increase over losses of $(1.50) per share from the same
Benzinga Insights

Thu Jun 18, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Newsdesk

Mon Jun 8, 2026

Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $56

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $65 to $56.
Benzinga Insights

Fri May 15, 2026

PAVmed Q1 2026 Earnings Call Transcript
Benzinga Newsdesk

Fri May 15, 2026

PAVmed Q1 Adj. EPS $(1.17) Misses $(0.70) Estimate, Sales $22.000K Miss $74.000K Estimate.

PAVmed (NASDAQ:PAVM) reported quarterly losses of $(1.17) per share which missed the analyst consensus estimate of $(0.70) by 67.14 percent. This is a 44.29 percent increase over losses of $(2.10) per share from the same
Benzinga Insights

Fri May 15, 2026

Earnings Scheduled For May 15, 2026
Benzinga Insights

Wed May 6, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Newsdesk

Thu Apr 23, 2026

Lucid Diagnostics Prices Underwritten Registered Direct Offering Of 18M Common Shares At $1.00 Per Share

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the pricing of an